Put $500 Into These 3 Cryptos and Watch It Grow Into a Lambo by 2026
Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims
Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.
